BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 9366517)

  • 1. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain.
    Sakamoto Y; Yoshida M; Semba K; Hunter T
    Oncogene; 1997 Oct; 15(17):2001-12. PubMed ID: 9366517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein.
    Wang ZY; Qiu QQ; Gurrieri M; Huang J; Deuel TF
    Oncogene; 1995 Mar; 10(6):1243-7. PubMed ID: 7700651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
    Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
    Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel replication inhibitory function of the developmental regulator/transcription repressor protein WT1 encoded by the Wilms' tumor gene.
    Anant S; Axenovich SA; Madden SL; Rauscher FJ; Subramanian KN
    Oncogene; 1994 Nov; 9(11):3113-26. PubMed ID: 7936634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
    Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
    Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells.
    Nichols KE; Re GG; Yan YX; Garvin AJ; Haber DA
    Cancer Res; 1995 Oct; 55(20):4540-3. PubMed ID: 7553624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain.
    Deuel TF; Guan LS; Wang ZY
    Biochem Biophys Res Commun; 1999 Jan; 254(1):192-6. PubMed ID: 9920756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional properties of WT1.
    Haber DA; Englert C; Maheswaran S
    Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
    McCoy C; McGee SB; Cornwell MM
    Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
    Zhang X; Xing G; Saunders GF
    Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional regulation of 5-aminolevulinate synthase by phenobarbital and cAMP-dependent protein kinase.
    Varone CL; Giono LE; Ochoa A; Zakin MM; Cánepa ET
    Arch Biochem Biophys; 1999 Dec; 372(2):261-70. PubMed ID: 10600163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
    Morris JF; Madden SL; Tournay OE; Cook DM; Sukhatme VP; Rauscher FJ
    Oncogene; 1991 Dec; 6(12):2339-48. PubMed ID: 1662794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1.
    Li RS; Law GL; Seifert RA; Romaniuk PJ; Morris DR
    Exp Cell Res; 1999 Feb; 247(1):257-66. PubMed ID: 10047468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
    Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
    Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1.
    Kim JM; Hong Y; Semba K; Kim S
    Biochem Biophys Res Commun; 2000 Jan; 267(1):59-63. PubMed ID: 10623574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of WT1 target gene expression in stably transfected cell lines.
    Thäte C; Englert C; Gessler M
    Oncogene; 1998 Sep; 17(10):1287-94. PubMed ID: 9771972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.